L -Carnitine-Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.

MLA

Fink, Matthias A., et al. “L -Carnitine-Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 25, no. 9, May 2019, pp. 2874–86. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-18-2380.

APA

Fink, M. A., Paland, H., Herzog, S., Grube, M., Vogelgesang, S., Weitmann, K., Bialke, A., Hoffmann, W., Rauch, B. H., Schroeder, H. W. S., & Bien-Möller, S. (2019). L -Carnitine-Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 25(9), 2874–2886. https://doi.org/10.1158/1078-0432.CCR-18-2380

Chicago

Fink, Matthias A, Heiko Paland, Susann Herzog, Markus Grube, Silke Vogelgesang, Kerstin Weitmann, Angela Bialke, et al. 2019. “L -Carnitine-Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25 (9): 2874–86. doi:10.1158/1078-0432.CCR-18-2380.